SGLT2 Inhibitor Use Linked to Lower Risk for Heart Failure, Death in Type 2 Diabetes
There was no association between initiation of SGLT2 inhibitors and other glucose-lowering drugs and the onset of atrial fibrillation.
There are no clear benefits or harms to choosing short-acting insulin analogs over regular human insulin for nonpregnant, adult individuals with type 2 diabetes.
Compared with GLP-1 receptor agonists, initiation of canagliflozin use for treatment of type 2 diabetes was not associated with increased risk for fracture.
Patients with T2D who initiated second-line antidiabetic medication therapy demonstrated similar CV risk after starting GLP-1 receptor agonists, SGLT-2 inhibitors, and DPP-4 inhibitors, which was below the threshold of harm.